Early-onset growth hormone treatment in Prader-Willi syndrome attenuates transition to severe obesity

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10496058" target="_blank" >RIV/00179906:_____/25:10496058 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/25:00143765 RIV/61988987:17110/25:A2603DNW RIV/44555601:13450/25:43899168 RIV/00216208:11120/25:43928263 a 11 dalších

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=JGwMkZsIuJ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=JGwMkZsIuJ</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1515/jpem-2024-0463" target="_blank" >10.1515/jpem-2024-0463</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Early-onset growth hormone treatment in Prader-Willi syndrome attenuates transition to severe obesity

Popis výsledku v původním jazyce

OBJECTIVES: Subsequent to early life feeding issues, children with Prader-Willi syndrome (PWS) develop hyperphagia and severe obesity. Growth hormone (GH) therapy has been approved in PWS to improve growth, body composition, and BMI. We aimed to clarify the role of age at GH therapy onset on growth and BMI trajectories in children with PWS. METHODS: We analyzed height and BMI in 114 patients (58 boys) from REPAR - Czech national GH registry. From them, 69 started GH therapy prior to 2 y/o (age 0.8 +- 0.4 years; mean +- SD; early-onset group [EO]), and 45 later (age 7.1 +- 4.1 years; late-onset group [LO]). RESULTS: Height-SDS before therapy was similar in all (EO: -1.9 +- 1.2 [mean +- SD]; LO: -1.7 +- 1.1). After the first year of GH therapy, height-SDS in the EO group increased to -1.0 +- 1.2, in the LO group to -0.9 +- 1.1. After 5 years, height fully normalized in all (-0.1 +- 1.1 SDS). The LO children were already obese at treatment initiation (BMI-SDS: 2.9 +- 2.2), and their BMI-SDS decreased after 1 year of GH therapy by 0.9 (p=0.003). The weight in EO children was below average before GH treatment (BMI-SDS: -0.9 +- 1.2) and their BMI-SDS increased to the overweight range of 1.3 +- 2.2 (p&lt;0.001) within the oncoming 3 years. Albeit BMI-SDS was around the obesity limit in most children after 5 years on GH therapy, the highest lifetime BMI-SDS was lower in EO (2.2 +- 2.6) than in LO (3.7 +- 2.2; p&lt;0.001). CONCLUSIONS: GH treatment in PWS normalizes body height. After 5 years of GH therapy, BMI-SDS in EO and LO groups are similar; however, the EO group is exposed to lower maximal BMI-SDS values.

Název v anglickém jazyce

Early-onset growth hormone treatment in Prader-Willi syndrome attenuates transition to severe obesity

Popis výsledku anglicky

OBJECTIVES: Subsequent to early life feeding issues, children with Prader-Willi syndrome (PWS) develop hyperphagia and severe obesity. Growth hormone (GH) therapy has been approved in PWS to improve growth, body composition, and BMI. We aimed to clarify the role of age at GH therapy onset on growth and BMI trajectories in children with PWS. METHODS: We analyzed height and BMI in 114 patients (58 boys) from REPAR - Czech national GH registry. From them, 69 started GH therapy prior to 2 y/o (age 0.8 +- 0.4 years; mean +- SD; early-onset group [EO]), and 45 later (age 7.1 +- 4.1 years; late-onset group [LO]). RESULTS: Height-SDS before therapy was similar in all (EO: -1.9 +- 1.2 [mean +- SD]; LO: -1.7 +- 1.1). After the first year of GH therapy, height-SDS in the EO group increased to -1.0 +- 1.2, in the LO group to -0.9 +- 1.1. After 5 years, height fully normalized in all (-0.1 +- 1.1 SDS). The LO children were already obese at treatment initiation (BMI-SDS: 2.9 +- 2.2), and their BMI-SDS decreased after 1 year of GH therapy by 0.9 (p=0.003). The weight in EO children was below average before GH treatment (BMI-SDS: -0.9 +- 1.2) and their BMI-SDS increased to the overweight range of 1.3 +- 2.2 (p&lt;0.001) within the oncoming 3 years. Albeit BMI-SDS was around the obesity limit in most children after 5 years on GH therapy, the highest lifetime BMI-SDS was lower in EO (2.2 +- 2.6) than in LO (3.7 +- 2.2; p&lt;0.001). CONCLUSIONS: GH treatment in PWS normalizes body height. After 5 years of GH therapy, BMI-SDS in EO and LO groups are similar; however, the EO group is exposed to lower maximal BMI-SDS values.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Pediatric Endocrinology &amp; Metabolism

ISSN

0334-018X

e-ISSN

2191-0251

Svazek periodika

38

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

8

Strana od-do

525-532

Kód UT WoS článku

001443915200001

EID výsledku v databázi Scopus

2-s2.0-105000187861